Rhenman & Partners Asset Management AB Purchases 79,000 Shares of Ra Pharmaceuticals Inc (NASDAQ:RARX)

Rhenman & Partners Asset Management AB increased its position in shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) by 52.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 229,000 shares of the company’s stock after buying an additional 79,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Ra Pharmaceuticals were worth $6,886,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of RARX. BlackRock Inc. grew its holdings in shares of Ra Pharmaceuticals by 29.0% during the fourth quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock worth $48,142,000 after buying an additional 595,328 shares in the last quarter. FMR LLC grew its holdings in shares of Ra Pharmaceuticals by 454.2% during the fourth quarter. FMR LLC now owns 413,389 shares of the company’s stock worth $7,524,000 after buying an additional 338,801 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Ra Pharmaceuticals by 407.0% during the fourth quarter. Millennium Management LLC now owns 412,066 shares of the company’s stock worth $7,500,000 after buying an additional 330,788 shares in the last quarter. Spark Investment Management LLC bought a new position in shares of Ra Pharmaceuticals during the first quarter worth about $3,458,000. Finally, Candriam Luxembourg S.C.A. grew its holdings in shares of Ra Pharmaceuticals by 16.5% during the first quarter. Candriam Luxembourg S.C.A. now owns 1,024,000 shares of the company’s stock worth $22,939,000 after buying an additional 145,000 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

In related news, insider Simon Read sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $22.25, for a total transaction of $222,500.00. Following the completion of the transaction, the insider now directly owns 8,521 shares of the company’s stock, valued at $189,592.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alonso Ricardo sold 2,857 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $23.72, for a total value of $67,768.04. Following the transaction, the insider now directly owns 11,428 shares of the company’s stock, valued at $271,072.16. The disclosure for this sale can be found here. Insiders have sold 33,452 shares of company stock valued at $970,463 over the last three months. Insiders own 4.30% of the company’s stock.

RARX has been the subject of a number of research reports. Jefferies Financial Group increased their price objective on Ra Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, June 18th. BidaskClub upgraded Ra Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 3rd. ValuEngine raised Ra Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. Svb Leerink started coverage on Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They set an “outperform” rating and a $33.00 price target for the company. Finally, SunTrust Banks increased their price target on Ra Pharmaceuticals to $42.00 and gave the company a “buy” rating in a research report on Friday, May 17th. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $37.73.

NASDAQ RARX traded down $1.03 during trading hours on Friday, hitting $31.95. 16,998 shares of the company traded hands, compared to its average volume of 493,803. The stock has a 50-day simple moving average of $30.54. Ra Pharmaceuticals Inc has a twelve month low of $8.67 and a twelve month high of $36.96. The company has a quick ratio of 20.10, a current ratio of 20.10 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.40 billion, a PE ratio of -15.53 and a beta of 1.23.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.02. As a group, research analysts forecast that Ra Pharmaceuticals Inc will post -1.8 EPS for the current fiscal year.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: How to build a Fibonacci channel

Want to see what other hedge funds are holding RARX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ra Pharmaceuticals Inc (NASDAQ:RARX).

Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.